**Key points:**

1. Survival outcomes of a poor prognosis subsite of head and neck cancer
2. Poor general health of patients
3. Low incidence compared with other mucosal squamous cell cancers, but often grouped with other subsites, which behave differently and are treated differently
4. Presentation with locally advanced disease
5. Impact of radical treatment

Most patients with hypopharyngeal squamous cell cancer (HPSCC) present with locally advanced disease and are unsuitable for active anti-cancer treatment. This is the first UK series evaluating only HPSCC in a contemporary H&N cancer practice.

**Survival outcomes in Hypopharyngeal cancer in the West of Scotland Cancer Network**

**Introduction**

Approximately 5% 1 of all mucosal head and neck (H&N) squamous cell cancers (SCC) arise from the hypopharynx. 1 Patients with hypopharyngeal SCC (HPSCC) tend to have a poor prognosis compared with other subsites with reported 5-year survival of 27% in the UK.2 Most patients (80%) have stage III/IV disease at presentation.3

There are very few HPSCC-specific studies and this subsite is not well represented in more general H&N SCC trials. Thus, deciding the best treatment plan is difficult and relies on the expertise of an experienced multi-disciplinary team (MDT).4

Patient fitness for treatment complicates matters further. The incidence of H&N cancer increases with age and is closely correlated with deprivation1 and the associated disproportionate burden of smoking, alcohol use and ill health.

The aim of this series was to review outcomes of patients with HPSCC in our cancer network.

**Materials and methods**

This retrospective study included all patients with a histological or radiological diagnosis of HPSCC made from August 2016 to August 2018. They were identified from the cancer network MDT database. Subsites included pyriform fossa, post cricoid and posterior pharyngeal wall.

Data including patient demographics, treatment details, toxicity and disease control were extracted from case records.

Ethics statement

Patient data were used to evaluate standard of care treatment and reviewed only by members of the responsible clinical team, in compliance with data protection regulations. Approval for the project was given by the Caldicott guardian.

Diagnosis and Staging

In suitable patients, examination under anaesthetic (EUA) and biopsy of the primary site was carried out to allow clinical staging and histological diagnosis. A radiological diagnosis was made when the patient was unsuitable for histological confirmation and was confirmed by the MDT. Every patient underwent cross-sectional imaging with a contrast enhanced CT scan of head, neck, chest and upper abdomen. FDG PET-CT was undertaken on a clinical judgement, generally for those with advanced disease, or with suspicion of distant metastases. Each case was discussed at the regional MDT meeting to confirm staging (according to the American Joint Committee on Cancer: 7th edition Cancer Staging (AJCC) 7th edition) and recommend treatment.

Primary surgery

Surgical approaches included resection of primary site only, or with unilateral, bilateral or central neck compartment dissection.

Adjuvant radiotherapy (RT) was recommended for established pathological risk factors, especially in the presence of several features (pT3-4, pN1-3, vascular/lymphatic/perineural invasion, close (1-5mm) mucosal resection margins). Those with involved margins (<1mm) or extranodal extension (ENE) were also considered for concurrent chemoradiotherapy (CRT) if eligible for platinum-based chemotherapy.

Radiotherapy/chemoradiotherapy

All patients underwent RT with Volumetric Arc Modulated Therapy (VMAT). Patients receiving RT as primary treatment received 65Gy/30# to areas of gross disease and involved nodal levels and 54Gy/30# to areas at risk of microscopic disease as per international guidelines.5 Post-operative RT was 60Gy/30# to the surgical bed and involved nodal levels, and 54Gy/30# elective dose. Patients with ENE or involved margins received 65Gy/30# to these high risk areas. Consensus for RT target volumes was achieved through consultant-led team peer-review. Concurrent chemotherapy was cisplatin 100mg/m2 on day 1 and 22 of RT for those eligible.

Chemotherapy alone

Chemotherapy alone was administered in the induction and palliative settings. Regimens included carboplatin AUC 5 and paclitaxel 175mg/m2 day 1, q21 and carboplatin AUC 5 day 1/5FU 750mg/m2/day 1-4, q21 for up to 6 cycles.

Statistical Analysis

Follow-up and survival statistics were calculated from the diagnosis until death or date of censor. Actuarial 1 and 2 year rates for overall survival (OS) were estimated using the Kaplan-Meier method.

**Results**

Patient and disease characteristics

118 patients were evaluable. 8 (6.7%) patients had a radiological diagnosis, the remainder were biopsy proven HPSCC. Patient and tumour characteristics are presented in Table 1. 26.3% had a prior cancer diagnosis with 16% having a previous H&N cancer.

Treatments and outcomes

Table 2 shows the treatment modalities delivered and outcomes, stratified by stage of disease. All patients had a minimum of 2 years follow-up. The probability of survival at 24 months was higher in patients of good performance status (PS 0-1: 41.7%, 95% CI 29.7-53.2% Vs. PS ≥2: 27.5%, 95% CI 13.9-43.0%). Patients aged 70 years or over had a lower probability of survival at 24 months compared to those under 70 (<70yrs 44.5%, 95% CI 27.1 – 55.9% Vs ≥70yrs 24.4%, 95% CI 12.6 – 38.3). 57 (48.3%) of the 118 patients were treated with radical intent, of which 19 (33%) died at time of follow-up. 14 of these deaths were cancer related and 5 were from other causes. The median time from primary surgery to adjuvant RT was 17 weeks.

*Stage 1 and 2*

There were 16 patients (13.6% of whole cohort) with early stage disease. The median survival for this group was 15.5 months. Of the 3 patients who had primary surgery, adjuvant RT was indicated for 1 patient due to close margins.

*Stage 3*

Fifteen patients (12.7%) had stage 3 disease. The median OS for these patients was 26.5 months.

*Stage 4a/b*

# The majority of the cohort had stage 4a or 4b disease – 82 patients (69.5%). The median survival for this group was 21 months. Despite 19 patients undergoing primary surgery, adjuvant RT was delivered in only 7 (36.8%). Reasons for no adjuvant RT were patient choice, patient fitness and early disease recurrence.

*Stage 4c*

The 5 patients who had stage 4c hypopharyngeal cancer were all managed with best supportive care. The median OS was 1.5 months for these patients.

**Discussion**

This is the first UK series evaluating only HPSCC in a contemporary H&N cancer practice. It illustrates that the majority of patients present with locally advanced disease and survival remains poor despite technological advances in diagnostic and treatment modalities. Nearly half of our patients were managed with supportive care only. While this was highest in the advanced disease setting, 25% of patients with early stage disease were not suitable for active treatment. This demonstrates the challenges encountered in delivering treatment to this group of patients.

Comparisons to other studies

Of patients who were suitable for active treatment, single modality surgery or RT appear to have equivalent outcomes in early stage disease. Patients with stage 3 disease may be optimally treated with combined modality therapy, either surgery plus adjuvant RT or primary CRT. This is in keeping with data from Tsai et al 6 where OS rates in the primary surgery and CRT groups were similar. For patients with stage 4a/b disease highest survival was achieved for combined modality therapy of surgery and adjuvant RT, again this is in keeping with earlier publications.6,7 However, prior to embarking on this course, the likelihood of the patient being able to complete multi-modality treatment in a timely fashion must be considered.8 Our data demonstrates this is feasible in the minority.

For patients treated radically the most common site of recurrence was loco-regional. The recently published UK Phase III ART-DECO study also found this to be the case.9 This trial examined dose escalated intensity-modulated radiotherapy (IMRT) in patients with locally advanced laryngeal and hypopharyngeal cancers finding it did not improve locoregional control (LRC) compared to standard of care. Improved LRC remains therefore an unmet need in locally advanced HPSCC.

Limitations

Given the retrospective nature of our own and previous work it remains uncertain whether selection bias contributes to the apparent survival benefit seen with multi-modality therapy including primary surgery. This limitation of our work and the lack of toxicity and patient reported quality of life data is acknowledged along with our modest numbers. However, our cohort of this rare SCC were captured over a short time period, meaning approaches to diagnosis and treatment are homogeneous and reflective of contemporary practice.

Clinical Applicability

While multi-modality therapy may offer improved outcomes it carries significant morbidity and mortality and survival remains poor for the majority of patients. Clinical factors such as age, disease stage and patient performance status may aid prognostication but do not predict outcome from treatment. Biomarkers are urgently needed to identify patients who may benefit most from intensified treatment. Improving early detection and optimisation of patients’ fitness for treatment are also crucial. Our work pre-dates the emergence of the immune checkpoint inhibitor pembrolizumab in the 1st line palliative setting in H&N SCC.10 For a small proportion of patients this treatment offers a durable response and prolonged survival and may offer an alternative to radical treatment in those with locally advanced disease.

**Conclusions**

Most patients with HPSCC present with locally advanced disease and are unsuitable for active anti-cancer treatment. For those treated radically the pattern of treatment failure is loco-regional. A multimodality approach for locally advanced disease with surgery and radiotherapy appears to be advantageous in terms of survival.

**References:**

1. Office for National Statistics. Life expectancy for local areas of the UK between 2001 to 2003 and 2017 to 2019 [Internet]. United Kingdom: White C, Rea M. [updated 2021 Sept 23rd; cited 2021 Jan 11]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandlifeexpectancies/bulletins/lifeexpectancyforlocalareasoftheuk/between2001to2003and2018to2020
2. Cancer Research UK. Head and neck cancer survival statistics [Internet]. United Kingdom: [updated 2016 Oct 19th; cited 2021 Jan 11]. Available from: [https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/head-and-neck-cancers/survival#heading-Zero](https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/head-and-neck-cancers/survival" \l "heading-Zero)
3. Pracy P, Loughran S, Good J, Parmar S, Goranova R. Hypopharyngeal cancer. In Paleri V, Roland N, editors. United Kingdom National Multidisciplinary Guidelines
4. The Journal of Laryngology and Otology [Internet]. United Kingdom: Cambridge University Press; 2016 [cited 2021 Jan 11]. Page 104-110. Available from: <https://www.cambridge.org/core/journals/journal-of-laryngology-and-otology/article/hypopharyngeal-cancer-united-kingdom-national-multidisciplinary-guidelines/3AB4267CA8BC22A3E528E4C9093DAC43>
5. Biau J, Lapeyre M, Troussier I, Budach W, Giralt J, Gregoire V et al. Selection of lymph node target volumes for definitive head and neck radiation therapy: a 2019 Update. Radiotherapy and Oncology. 2019 Jan 13. 134:1-9.
6. Tsai Y-T, Chen W-C, Chein C-Y, Hsu C-M, Lee Y-C, Tsai M-S et al. Treatment patterns and survival outcomes of advanced hypopharyngeal squamous cell carcinoma. World Journal of Surgical Oncology [Internet]. 2020 May [cited 2021 Sept 24]. 18 (82). Available from: https://doi.org/10.1186/s12957-020-01866-z
7. Hochfelder C, Mehta V, Kabarriti R, McGinn A, Castellucci E, Ow T. Survival analysis of patients with advanced hypopharyngeal cancer comparing patients who received primary surgery to those who received chemoradiation: An analysis of the NCDB. 2021 Oct. [cited 2021 Nov 18]. 121:105470. Available from: https://doi.org/10.1016/j.oraloncology.2021.105470
8. Grayboyes E, Garrett-Mayer E, Ellis M, Sharma A, Wahlquist A, Lentsch E et al. Effect of Time to Initiaion of Postoperative Radiation Therapy on Survival in Surgically-Managed Head and Neck Cancer. Cancer [Internet]. 2017 Dec 15 [cited 2021 December 15]. 123(24): 4841-4850. Available from: https://doi.org/10.1002/cncr.30939
9. Nutting C, Griffin C, Sanghera P, Foran B, Beasley M, Bernstein D et al. Dose-escalated intensity-modulated radiotherapy in patients with locally advanced laryngeal and hypopharyngeal cancers: ART DECO, a phase III randomised controlled trial. European Journal of Cancer. 2021 May 9. 153 (2021): 242-256
10. Burtness B, Harrington K, Greil R, Soulieres D, Tahara M, Castro J G et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. The Lancet. 2019 Oct 31. 394 (10212): 1915-1928